A 6-year follow-up study of 21 SSc patients illustrated stable BAFF levels in 52%, decreased BAFF levels in 33% and increased, over the time, BAFF levels in 14% compared to baseline levels. Here, TNFSF13B is linked to systemic sclerosis.